SynthesisEuropean journal of nuclear medicine and molecular imaging2025
Insights into pet-based radiogenomics in oncology: an updated systematic review.
Synthesis in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- From center to edge: Prognostic implications of spatial metabolic heterogeneity, normalized hotspot-to-centroid and perimeter distance, on PET imaging. A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.Frontiers in immunology · 2026Pooled it
- Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework.European journal of nuclear medicine and molecular imaging · 2026Article
- Large axial field of view PET/CT - Not just a longer PET gantry.Zeitschrift fur medizinische Physik · 2026Review
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- B-Mode Ultrasound Radiomics for Differentiating Benign and Malignant Small Hyperechoic Renal Masses: An Exploratory Single-Center Experience.Journal of imaging · 2026Article
- Machine learning-based models for tumor mutation burden prediction in gastrointestinal cancers: a systematic review and meta-analysis.Discover oncology · 2026Review
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- Integration of Conventional and Radiomic Features From Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging for Multimodal Prediction of Symptomatic Carotid Atherosclerotic Plaques.Journal of the American Heart Association · 2026Article
- AI-powered radiogenomics: imaging-driven diagnosis and discovery of cancer's molecular and cellular landscape.Molecular genetics and genomics : MGG · 2026Review
- Editorial: Recent developments in artificial intelligence and radiomics.Frontiers in medicine · 2026Article
- PET-guided therapy: synergies, strategies, and future directions in external beam radiation therapy and radiopharmaceutical therapy.Frontiers in medicine · 2026Review
- A radiogenomics study onBMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study systematically reviews current evidence on radiogenomics applied to positron emission tomography (PET) imaging across oncological diseases. The primary objective is to evaluate how PET-based radiogenomics aids in understanding tumor biology, prognostic stratification, and clinical outcome prediction, while identifying methodological challenges in the field.
methodsA systematic review was conducted following PRISMA guidelines, focusing on English-language studies indexed in Scopus, PubMed, and Web of Science until October 31, 2024. Inclusion criteria targeted original research articles involving human oncology studies using radiomics and genomics in a comprehensive "omics" framework. Data extraction included patient cohorts, radiopharmaceuticals and statistical methods. Studies were assessed for methodological rigor and reporting quality according to radiomics quality scores (RQS 2.0).
resultsEighteen studies involving 1780 patients were included, with 75.8% focused on lung cancer. Most studies were retrospective (72.2%) and single-center (77.7%). The primary radiopharmaceutical was [
conclusionPET-based radiogenomics holds significant potential for advancing precision oncology by capturing tumor heterogeneity and improving prognostic stratification. However, methodological limitations, particularly regarding study design and data transparency, hinder its clinical applicability. Future research should prioritize multicentric designs, robust external validations, and enhanced standardization to fully realize the discipline's potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.